All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
"We've finally pushed open a door to an entirely new pathway of potential approaches to treat cancer," Walter Klemp, chair and CEO of Moleculin Biotech Inc., said about the initiation of an investigator-led phase I study of STAT3 inhibitor WP-1066 in glioblastoma at MD Anderson Cancer Center. "People have been pounding on this door for a long time, and it was painful getting here, but now it's opened."